BCL2 and acute lymphoblastic leukemia: Expanded human T-ALL (N = 3) and ETP-ALL (N = 2) samples were then exposed to single inhibitors against LSD1 (GSK-LSD1, SP2509), JAK1/2 (Ruxo) or BCL2 (ABT-199) or combinations of GSK-LSD1/Ruxo, GSK-LSD1/ABT-199, SP2509/Ruxo or SP2509/ABT-199.